HomeNewsBusinessMarketsPharma sector: RBS picks Cipla, Lupin; shuns Dr Reddy's

Pharma sector: RBS picks Cipla, Lupin; shuns Dr Reddy's

Prakash Agarwal, Equity Analyst - India Pharma, RBS is positive on Lupin and advises investor to buy on dips. In the largecap space, Cipla is his top pick He has a target price of Rs 371 on the stock. In the midcap space, he likes Glenmark Pharma.

July 08, 2011 / 08:51 IST
Story continues below Advertisement

Your browser doesn't support HTML5 video.

Prakash Agarwal, Equity Analyst - India Pharma, RBS is positive on Lupin and advises investor to buy on dips. In the largecap space, Cipla is his top pick He has a target price of Rs 371 on the stock. In the midcap space, he likes Glenmark Pharma.

However, he is bearish on Dr Reddy
first published: Jul 7, 2011 02:04 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!